Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L DAVILA

Showing results (81-90 of 98) with videos related to

Pageof 10
Sort By:
Transplantation and Cellular Therapy|September 29, 2022
Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including DialysisAnthony C Wood, Ariel Perez Perez, Brian Arciola, et al.
Blood|July 24, 2024
JAK2/mTOR inhibition fails to prevent acute GVHD despite reduced Th1/Th17 cells: final phase 2 trial resultsJoseph Pidala, Shernan G Holtan, Kelly Walton, et al.
Blood|August 19, 2011
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemiasRenier J Brentjens, Isabelle Rivière, Jae H Park, et al.
Haematologica|April 25, 2020
Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphomaJennifer M Logue, Elisa Zucchetti, Christina A Bachmeier, et al.
Blood Cancer Discovery|February 2, 2026
Endogenous CD28 drives the persistent activity of CAR T cells in myeloma and lymphoma modelsMackenzie M Lieberman, Jason H Tong, Nkechi U Odukwe, et al.
Cell|November 6, 2018
Distinct Regulation of Th17 and Th1 Cell Differentiation by Glutaminase-Dependent MetabolismMarc O Johnson, Melissa M Wolf, Matthew Z Madden, et al.
Blood Advances|October 14, 2021
A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host diseaseAleksandr Lazaryan, Stephanie Lee, Mukta Arora, et al.
Journal for Immunotherapy of Cancer|July 29, 2025
Comparison of axicabtagene ciloleucel and tisagenlecleucel patient CAR-T cell products by single-cell RNA sequencingXiaoqing Yu, Michael D Jain, Meghan A Menges, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 16, 2025
Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B cell LymphomaKhushali Jhaveri, Ram Thapa, Dalia Ercan, et al.
Blood Advances|April 8, 2025
Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucelSatabdi Saha, Lubna Rehman, Abdur Rehman, et al.
Pageof 10

Showing results (81-90 of 98) with videos related to

Sort By:
Pageof 10
Transplantation and Cellular Therapy|September 29, 2022
Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including DialysisAnthony C Wood, Ariel Perez Perez, Brian Arciola, et al.
Blood|July 24, 2024
JAK2/mTOR inhibition fails to prevent acute GVHD despite reduced Th1/Th17 cells: final phase 2 trial resultsJoseph Pidala, Shernan G Holtan, Kelly Walton, et al.
Blood|August 19, 2011
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemiasRenier J Brentjens, Isabelle Rivière, Jae H Park, et al.
Haematologica|April 25, 2020
Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphomaJennifer M Logue, Elisa Zucchetti, Christina A Bachmeier, et al.
Blood Cancer Discovery|February 2, 2026
Endogenous CD28 drives the persistent activity of CAR T cells in myeloma and lymphoma modelsMackenzie M Lieberman, Jason H Tong, Nkechi U Odukwe, et al.
Cell|November 6, 2018
Distinct Regulation of Th17 and Th1 Cell Differentiation by Glutaminase-Dependent MetabolismMarc O Johnson, Melissa M Wolf, Matthew Z Madden, et al.
Blood Advances|October 14, 2021
A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host diseaseAleksandr Lazaryan, Stephanie Lee, Mukta Arora, et al.
Journal for Immunotherapy of Cancer|July 29, 2025
Comparison of axicabtagene ciloleucel and tisagenlecleucel patient CAR-T cell products by single-cell RNA sequencingXiaoqing Yu, Michael D Jain, Meghan A Menges, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 16, 2025
Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B cell LymphomaKhushali Jhaveri, Ram Thapa, Dalia Ercan, et al.
Blood Advances|April 8, 2025
Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucelSatabdi Saha, Lubna Rehman, Abdur Rehman, et al.
Pageof 10